European Leukemia Trial Registry
Trial: ALL Aplidin

More Details
Title Aplidin in relapsed/refractory ALL
Scientific Title A Phase II multicenter, open-label, clinical and pharmacokinetic study of Aplidin ® (APLD) as a 1-hour weekly IV infusion, in patients with relapsed or refractory acute lymphoblastic leukemia (ALL)
Short Title ALL Aplidin
Trialgroup GMALL
Type of Trial multicentric
Disease Acute lymphoblastic leukemia(ALL) All subtypes
Age >= 18 years
Status Closed
Start of Recruitment 24.10.2005
Leader Junghanß, Prof. Dr., Christian
Contactperson

principal investigator
Junghanß, Prof. Dr., Christian
Tel: +49 (0)381 494 7421
Fax: +49 (0)381 494 7422
Email: christian.junghanss@med.uni-rostock.de

Centre of Trial Universitätsklinikum Rostock
Shortprotocol Shortprotocol
created 06.07.2006 Anja Hellenbrecht
changed 05.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org